As stated by Dreijerink et al. in a letter to the editor (169), the decision to intensify breast cancer screening in MEN1 patients should not be taken lightly, and the dilemma is whether the benefits of detecting early stage cancers will outweigh the potential harms from the surveillance (i.e. earlier mammography and its attendant increased lifetime exposure to radiation) and the risk of false positives that can lead to unnecessary procedures, patient anxiety, and increased health care costs. Here, MEN1 is linked to breast carcinoma.